research Hormonal therapies for acne
Hormonal treatments can improve acne, but they come with potential side effects and risks.
Search
for
Sort by
Research
930-960 / 1000+ results 
research 17α-Acetoxy-6-bromo-16β-methylpregna-4,6-diene-3,20-dione
A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.
research Efficacy observation of tamsulosin combined finasteride on delay and prevention the progression of BPH
Tamsulosin and finasteride together effectively slow down and prevent BPH progression.
research Table of Contents
Second-generation antipsychotics offer no significant benefit over first-generation ones for schizophrenia.
research What's New: Newly Approved Drugs for Children
In 2001, the FDA approved 12 new drugs for children to treat allergies, asthma, ADHD, birth control, and other conditions.
research 1103 Derinat extends hair cycle at anagen phase by decreasing the level of TRPCs-mediated intracellular ROS accumulation in skin
Derinat helps extend hair growth by reducing harmful molecules in skin cells.
research Changes in expression of the δ subunit of the GABAAreceptor and in receptor function induced by progesterone exposure and withdrawal
Progesterone affects GABAA receptor function by altering δ subunit levels.
research Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase Inhibitor
Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
research Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia
Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.
research Real-life Data for Tenofovir Alafenamide Fumarate Treatment of Hepatitis B: the Pythagoras Cohort
Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
research Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
research Screening of synthetic and natural product databases: Identification of novel androgens and antiandrogens
Researchers found new potential treatments for conditions related to the androgen receptor, like male hormonal contraception, by testing thousands of compounds.
research A new strategy to modulate alopecia using a combination of two specific and unique ingredients.
A new hair loss treatment with two unique ingredients improved hair growth.
research Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin
Using minoxidil and anthralin together can improve hair regrowth in severe alopecia areata patients who didn't respond to individual treatments.
research Pharmacophore and Atom Based 3D QSAR Studies on the Novel 5-Alpha-Reductase Inhibitors
The developed model can predict effective 5-alpha-reductase enzyme inhibitors.
research Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
research Anti-Androgens
Effective treatments for excessive body hair in women include drugs that block androgens, sometimes combined with oral contraceptives.
research Treatment of chronic type B hepatitis in Southeast Asia.
Interferon therapy is a promising and safe treatment for hepatitis B in Southeast Asia.
research [Two drugs have a better outcome. Finasteride plus alpha blocker improves urine flow].
research An urticarial drug eruption caused by tofacitinib for alopecia universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
research Hormonal therapy in female pattern hair loss
Hormonal therapies help treat female hair loss, but results are slow and vary.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Androgenetic alopecia, hirsutism and hypertrichosis
Hair loss and excessive growth treated with various options, including new laser technology.
research Chemotropic Neomorphogenesis of Hemodynamically Active Hypervascular Patterns in Hare Skin by a Monocytic Polypeptide Mediator for Blood Vessel Growth (Monocyto-Angiotropin) Promotes Tissue Hyperfunction (Hair Growth)
Injecting monocyto-angiotropin into hare skin increases hair growth by forming new blood vessels.
research Comparison of combination therapy with tamsulosin and dutasteride or finasteride in patients with benign prostatic hyperplasia: a randomized clinical trial
Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.
research 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder
High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
research Diphenylcyclopropenone alleviates trachyonychia in alopecia universalis
research Th,-e mechanistic insights into the application of retinoids and possible adjunct therapeutic treatment to androgenic alopecia
Retinoids may improve hair growth in androgenic alopecia when used with other treatments.
research 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
The post hoc analysis of the ALLEGRO phase 2b/3 study evaluated the sustained efficacy of ritlecitinib, an oral JAK3/TEC inhibitor, in patients with alopecia areata over 48 weeks. Patients aged 12 and older with at least 50% scalp hair loss were treated with varying doses of ritlecitinib or placebo. Results showed that among those who responded to treatment at Week 24, over 85% with a SALT score ≤20 and over 68% with a SALT score ≤10 maintained their response through Week 48. Additionally, more than half of the patients with eyebrow and eyelash improvements sustained their response. Ritlecitinib was well tolerated, indicating its potential as an effective treatment for alopecia areata.